{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:24:06Z","timestamp":1793521446489,"version":"4.5.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a multifactorial, progressive neurodegenerative disorder that primarily affects dopaminergic neurons in the substantia nigra. In addition to hallmark motor symptoms, it manifests a wide range of nonmotor complications, including cognitive decline, neuropsychiatric symptoms, autonomic dysfunction, and comorbid metabolic and infectious diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This review aims to elucidate the molecular and cellular mechanisms underlying PD, explore the influence of genetic and environmental factors, evaluate current treatment limitations, and assess the clinical and socioeconomic burden globally. Emphasis is placed on emerging therapeutic avenues and innovative research directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A structured literature review was conducted using PubMed, Scopus, and Web of Science databases. The search included articles published between 2010 and 2025, using keywords: \u201cParkinson\u2019s disease,\u201d \u201c\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -synuclein,\u201d \u201cdopaminergic degeneration,\u201d \u201cferroptosis,\u201d \u201cdeep brain stimulation,\u201d \u201cstem cell therapy,\u201d and \u201cAI in PD diagnosis.\u201d\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The review highlights a multifactorial etiology involving\n                      <jats:italic>\u03b1<\/jats:italic>\n                      -synuclein pathology, oxidative stress, mitochondrial dysfunction, genetic mutations (SNCA, LRRK2, VPS35), environmental toxins, and gut dysbiosis. Comorbidities such as HIV, diabetes, and cardiovascular disorders exacerbate disease burden. While Levodopa remains the gold standard, its limitations necessitate combination therapy and adjunct modalities such as deep brain stimulation and nanocarrier-based drug delivery. Emerging approaches\u2014stem cell therapy, CRISPR-Cas9, and AI-enhanced diagnostics\u2014show promise.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PD management requires a paradigm shift toward precision medicine. Advancing research into biomarkers, immunotherapy, and systems biology, coupled with equitable access to care and early diagnosis tools, is critical to mitigating the global impact of PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2025.1617106","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:33:22Z","timestamp":1758173602000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Understanding Parkinson\u2019s disease: current trends and its multifaceted complications"],"prefix":"10.3389","volume":"17","author":[{"given":"Sameer A.","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapana","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e01063","DOI":"10.1002\/prp2.1063","article-title":"Pros and cons for statins use and risk of Parkinson's disease: an updated perspective","volume":"11","author":"Al-kuraishy","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","article-title":"Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease","volume":"25","author":"Barker","year":"2019","journal-title":"Nat. Med."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/ijms23020678","article-title":"Mechanistic insights expatiating the redox-active-metal-mediated neuronal degeneration in Parkinson\u2019s disease","volume":"23","author":"Behl","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson's disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.lanepe.2024.100870","article-title":"The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis","volume":"39","author":"Burchill","year":"2024","journal-title":"Lancet Reg. Health - Eur."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4951379","DOI":"10.1155\/2019\/4951379","article-title":"Analysis of the relationship between type II diabetes mellitus and Parkinson's disease: a systematic review","volume":"2019","author":"Camargo","year":"2019","journal-title":"Parkinson's Dis."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14802\/jmd.22141","article-title":"Current status and future perspectives on stem cell-based therapies for Parkinson's disease","volume":"16","author":"Cha","year":"2023","journal-title":"J. Mov. Disorders"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.3233\/JPD-223461","article-title":"Exploring the connection between the gut microbiome and Parkinson's disease symptom progression and pathology: implications for supplementary treatment options","volume":"12","author":"Chan","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/antiox9070597","article-title":"The role of oxidative stress in Parkinson\u2019s disease","volume":"9","author":"Chang","year":"2020","journal-title":"Antioxidants"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40801-023-00410-1","article-title":"Economic burden of Parkinson's disease: a multinational, real-world, cost-of-illness study","volume":"11","author":"Chaudhuri","year":"2024","journal-title":"Drugs Real World Outcomes"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41531-022-00222-9","article-title":"Gaps and roadmap of novel neuromodulation targets for treatment of gait in Parkinson\u2019s disease","volume":"8","author":"Cury","year":"2022","journal-title":"NPJ Parkinsons Dis."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1017\/S1431927622011953","article-title":"Identification of increased blood brain barrier permeability in the substantia nigra of the HIV-1 transgenic rat","volume":"28","author":"Denaro","year":"2022","journal-title":"Microsc. Microanal."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3233\/JPD-240019","article-title":"The body, the brain, the environment, and Parkinson\u2019s disease","volume":"14","author":"Dorsey","year":"2024","journal-title":"J. Parkinsons Dis."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12974-017-0935-1","article-title":"Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson\u2019s disease","volume":"14","author":"Eidson","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/jcm10112302","article-title":"Prevalence and clinical correlates of comorbid anxiety and panic disorders in patients with Parkinson's disease","volume":"10","author":"Elefante","year":"2021","journal-title":"J. Clin. Med."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnbeh.2016.00121","article-title":"Dopamine replacement therapy, learning and reward prediction in Parkinson's disease: implications for rehabilitation","volume":"10","author":"Ferrazzoli","year":"2016","journal-title":"Front. Behav. Neurosci."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.3390\/ijms22094643","article-title":"Genes implicated in familial Parkinson\u2019s disease provide a dual picture of nigral dopaminergic neurodegeneration with mitochondria taking center stage","volume":"22","author":"Franco","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1104393","DOI":"10.3389\/fcell.2023.1104393","article-title":"Serum inflammatory cytokines levels and the correlation analyses in Parkinson\u2019s disease","volume":"11","author":"Fu","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.61186\/nl.2.2.55","article-title":"Neural stem cell therapies: promising treatments for neurodegenerative diseases","volume":"2","author":"Gholamzad","year":"2023","journal-title":"Neurol. Lett."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.3233\/JPD-179005","article-title":"The synucleinopathies: twenty years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"16074","DOI":"10.3892\/br.2023.16074","article-title":"Parkinson's disease and cardiovascular involvement: edifying insights","volume":"18","author":"Grosu","year":"2023","journal-title":"Biomed. Rep."},{"key":"ref23","first-page":"017","article-title":"Parkinson\u2019s disease research by India: a scientometric assessment of publications output for the period 1990-2019","volume":"5","author":"Gupta","year":"2021","journal-title":"J. Brain Neurosci."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1212\/WNL.0000000000009946","article-title":"Deep brain stimulation in early-stage Parkinson disease: five-year outcomes","volume":"95","author":"Hacker","year":"2020","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/applmicrobiol3020030","article-title":"The role of an altered gut microbiome in Parkinson\u2019s disease: a narrative review","volume":"3","author":"Hashish","year":"2023","journal-title":"Appl. Microbiol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e9853","DOI":"10.7759\/cureus.9853","article-title":"Diabetes mellitus and Parkinson's disease: shared pathophysiological links and possible therapeutic implications","volume":"12","author":"Hassan","year":"2020","journal-title":"Cureus"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41531-018-0055-3","article-title":"Cognitive impairment in Parkinson\u2019s disease: current challenges and future prospects","volume":"4","author":"Hindle","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3171\/2018.8.JNS182081","article-title":"Long-term outcomes following deep brain stimulation for Parkinson's disease","volume":"132","author":"Hitti","year":"2019","journal-title":"J. Neurosurg."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0126660822334997241216062002","article-title":"Ai-driven innovations in assessing stress, anxiety, and mental health","volume":"21","author":"Inamdar","year":"2024","journal-title":"Curr. Psychiatry Res. Rev."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1248\/bpb.b22-00839","article-title":"CRISPR-Cas9-edited SNCA knockout human induced pluripotent stem cell-derived dopaminergic neurons and their vulnerability to neurotoxicity","volume":"46","author":"Inoue","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/cells12071012","article-title":"Microglia mediated neuroinflammation in Parkinson\u2019s disease","volume":"12","author":"Isik","year":"2023","journal-title":"Cells"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.18231\/j.jpbs.2023.011","article-title":"Drug repurposing: a futuristic approach in drug discovery","volume":"11","author":"Khan","year":"2023","journal-title":"J. Pharm. Biol. Sci."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.33588\/rn.75s04.2022217","article-title":"Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert. Tratamiento farmacol\u00f3gico de los s\u00edntomas motores de la enfermedad de Parkinson: actualizaci\u00f3n y recomendaciones de un experto","volume":"75","author":"Kulisevsky","year":"2022","journal-title":"Rev. Neurol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3390\/healthcare10071305","article-title":"Prevalence and risk factors of depression between patients with Parkinson's disease and their caregivers: a one-year prospective study","volume":"10","author":"Lee","year":"2022","journal-title":"Healthcare"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00702-022-02536-y","article-title":"Viruses, parkinsonism and Parkinson\u2019s disease: the past, present and future","volume":"129","author":"Leta","year":"2022","journal-title":"J. Neural Transm."},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.107917","volume-title":"Ethical and safety considerations in stem cell-based therapy for Parkinson\u2019s disease","author":"Li","year":"2023"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"6600944","DOI":"10.1155\/2022\/6600944","article-title":"Association of p53 with neurodegeneration in Parkinson's disease","volume":"2022","author":"Luo","year":"2022","journal-title":"Parkinson's Disease"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/0963689718820271","article-title":"Transplantation of human neural progenitor cells (NPC) into putamina of parkinsonian patients: a case series study, safety and efficacy four years after surgery","volume":"28","author":"Madrazo","year":"2019","journal-title":"Cell Transplant."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/biomedicines9030313","article-title":"Management of Antiretroviral Therapy with boosted protease inhibitors-Darunavir\/ritonavir or Darunavir\/Cobicistat","volume":"9","author":"Marin","year":"2021","journal-title":"Biomedicines"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/MDC3.12568","article-title":"Epidemiology of Parkinson's disease\u2014east versus west","author":"Masoom","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3390\/biom12091199","article-title":"The effect of aggregated alpha synuclein on synaptic and axonal proteins in Parkinson's disease\u2014a systematic review","volume":"12","author":"Murphy","year":"2022","journal-title":"Biomol. Ther."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fnins.2020.00494","article-title":"Nanotechnology: a promising approach for delivery of neuroprotective drugs","volume":"14","author":"Naqvi","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","article-title":"Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease","volume":"2","author":"Niethammer","year":"2017","journal-title":"JCI Insight"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"660","DOI":"10.4103\/aian.aian_779_21","article-title":"Annual cost of Care of Parkinson's disease and its determinants in North India - a cost of illness study with patient perspective","volume":"25","author":"Ola","year":"2022","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e202012095","DOI":"10.1083\/jcb.202012095","article-title":"The cell biology of Parkinson's disease","volume":"220","author":"Panicker","year":"2021","journal-title":"J. Cell Biol."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy","volume":"14","author":"Parkinson","year":"1817","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41531-023-00603-z","article-title":"Population fraction of Parkinson's disease attributable to preventable risk factors","volume":"9","author":"Payami","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41531-022-00296-w","article-title":"Comparative efficacy of surgical approaches to disease modification in Parkinson disease","volume":"8","author":"Rahimpour","year":"2022","journal-title":"NPJ Parkinson's Disease"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries\/territories from 1990 to 2019","volume":"9","author":"Rahman","year":"2025","journal-title":"Front. Pub. Health"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1212\/CON.0000000000001160","article-title":"Surgical therapies for Parkinson disease","volume":"28","author":"Rawls","year":"2022","journal-title":"Continuum"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"57956","DOI":"10.22214\/ijraset.2024.57956","article-title":"Parkinson disease","volume":"12","author":"Rode Karan Ganesh","year":"2024","journal-title":"IJRASET"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0115743624360618250507112532","article-title":"Unravelling LRRK2 pathways in Parkinson\u2019s disease: mechanisms and intricacies","volume":"20","author":"Sen","year":"2025","journal-title":"Curr. Signal Transduct. Ther."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/J.MPSUR.2018.03.007","article-title":"Medical management of risk factors for vascular disease","volume":"36","author":"Sharkey","year":"2018","journal-title":"Surgery"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0125899775373406250411104442","article-title":"The potential of coenzyme Q10 in Alzheimer\u2019s disease: reducing IL-17 induced inflammation and oxidative stress for neuroprotection","volume":"17","author":"Sharma","year":"2025","journal-title":"Curr. Drug Res. Rev."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e00453","DOI":"10.1002\/brb3.453","article-title":"Causes and factors related to dopamine agonist withdrawal in Parkinson\u2019s disease","volume":"6","author":"Su\u00e1rez Castro","year":"2016","journal-title":"Brain Behav."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"51655","DOI":"10.7759\/cureus.51655","article-title":"Neuropsychiatric disorders: bridging the gap between neurology and psychiatry","volume":"16","author":"Taslim","year":"2024","journal-title":"Cureus"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.17116\/jnevro202212211212","article-title":"Bolezn' Parkinsona i sakharnyi diabet 2-go tipa: svyaz' mekhanizmov patogeneza i obshchie terapevticheskie podkhody Parkinson's disease and type 2 diabetes mellitus: interrelation of pathogenetic mechanisms and general therapeutic approaches","volume":"122","author":"Troshneva","year":"2022","journal-title":"Zh. Nevrol. Psikhiatr. Im. S.S. Korsakova"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"9777","DOI":"10.3390\/ijms24119777","article-title":"Zooming into gut dysbiosis in Parkinson\u2019s disease: new insights from functional mapping","volume":"24","author":"Turco","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"8492619","DOI":"10.1155\/2017\/8492619","article-title":"DBS programming: an evolving approach for patients with Parkinson's disease","volume":"2017","author":"Wagle Shukla","year":"2017","journal-title":"Parkinson's Disease"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1231707","DOI":"10.3389\/fgene.2023.1231707","article-title":"Uncovering ferroptosis in Parkinson\u2019s disease via bioinformatics and machine learning, and reversed deducing potential therapeutic natural products","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Genet."},{"key":"ref61","volume-title":"World Health Organization. 2020. Deaths from Parkinson's disease dataset. Our World in Data. Global Health Estimates","year":"2020"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e2300965120","DOI":"10.1073\/pnas.2300965120","article-title":"Chemical disaggregation of alpha-synuclein fibrils as a therapy for synucleinopathies","volume":"120","author":"Wu","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.4103\/1673-5374.373710","article-title":"Cell replacement for Parkinson\u2019s disease: advances and challenges","volume":"18","author":"Xiao","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1186\/s12920-023-01493-2","article-title":"Identification of ferroptosis related biomarkers and immune infiltration in Parkinson\u2019s disease by integrated bioinformatic analysis","volume":"16","author":"Xing","year":"2023","journal-title":"BMC Med. Genet."},{"key":"ref65","volume-title":"Development of electrospun fibers for drug delivery (Bachelor\u2019s thesis)","author":"Zaguirre","year":"2023"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s12011-023-03750-9","article-title":"Dietary copper intake and risk of Parkinson\u2019s disease: a cross-sectional study","volume":"202","author":"Zeng","year":"2024","journal-title":"Biol. Trace Elem. Res."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000524208","article-title":"Trends in prevalence cases and disability-adjusted life-years of Parkinson's disease: findings from the global burden of disease study 2019","volume":"56","author":"Zhong","year":"2022","journal-title":"Neuroepidemiology"}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2025.1617106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:33:24Z","timestamp":1758173604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2025.1617106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":66,"alternative-id":["10.3389\/fnagi.2025.1617106"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2025.1617106","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1617106"}}